144 related articles for article (PubMed ID: 35166229)
1. Roles of metabolic tumor volume and total lesion glycolysis on 18F-FDG PET/CT, CA19-9 levels, and complete blood count parameters in predicting survival in patients with unresectable or metastatic pancreatic cancer.
Erdur E; Guzel Y; Yildirim OA; Poyraz K; Yildirim MS; Kaplan H
Ann Ital Chir; 2022; 93():85-95. PubMed ID: 35166229
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis on Preoperative ¹⁸F-FDG PET/CT in Patients with Pancreatic Cancer.
Lee JW; Kang CM; Choi HJ; Lee WJ; Song SY; Lee JH; Lee JD
J Nucl Med; 2014 Jun; 55(6):898-904. PubMed ID: 24711649
[TBL] [Abstract][Full Text] [Related]
3. Associations of volumetric whole-body
Araç E; Can C; Kömek H
Hell J Nucl Med; 2020; 23(1):40-47. PubMed ID: 32361716
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents.
Hwang SH; Cho A; Yun M; Choi YD; Rha SY; Kang WJ
Clin Nucl Med; 2017 May; 42(5):e235-e241. PubMed ID: 28288043
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of volume-based FDG PET/CT parameters in patients with locally advanced pancreatic cancer treated with chemoradiation therapy.
Choi HJ; Lee JW; Kang B; Song SY; Lee JD; Lee JH
Yonsei Med J; 2014 Nov; 55(6):1498-506. PubMed ID: 25323885
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of FDG PET/CT derived parameters in prediction of histopathological finding during the surgery in patients with pancreatic adenocarcinoma.
Myssayev A; Myssayev A; Ideguchi R; Eguchi S; Adachi T; Sumida Y; Tobinaga S; Uetani M; Kudo T
PLoS One; 2019; 14(1):e0210178. PubMed ID: 30629646
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Value of Metabolic and Volumetric Parameters of Preoperative FDG-PET/CT in Patients With Resectable Pancreatic Cancer.
Im HJ; Oo S; Jung W; Jang JY; Kim SW; Cheon GJ; Kang KW; Chung JK; Kim EE; Lee DS
Medicine (Baltimore); 2016 May; 95(19):e3686. PubMed ID: 27175707
[TBL] [Abstract][Full Text] [Related]
8. Heterogeneity index evaluated by slope of linear regression on
Kim YI; Kim YJ; Paeng JC; Cheon GJ; Lee DS; Chung JK; Kang KW
Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):1995-2003. PubMed ID: 28634684
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of 18F-FDG PET/CT indices in metastatic renal cell cancer and evaluation of revised IMDC risk model by including 18F-FDG PET-CT parameters.
Arikan R; Ozguven S; Telli TA; Isik S; Demircan NC; Basoglu T; Yasar A; Celebi A; Filizoglu N; Ustun HS; Tinay I; Ones T; Turoglu HT; Erdil TY; Ozturk MA; Ercelep O; Bayoglu V; Kostek O; Dane F; Yumuk PF
Acta Radiol; 2023 May; 64(5):2040-2049. PubMed ID: 36447438
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of metabolic tumor volume and total lesion glycolysis in patients with advanced cervical carcinoma.
Calles-Sastre L; Mucientes-Rasilla J; San-Frutos Llorente LM; Royuela A; Garcia-Espantaleón Navas M; Herrero Gámiz S; Pérez-Medina T
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019; 38(1):17-21. PubMed ID: 30366731
[TBL] [Abstract][Full Text] [Related]
11. Total Lesion Glycolysis on 18F-FDG PET/CT Is a Better Prognostic Factor Than Tumor Dose on 90Y PET/CT in Patients With Hepatocellular Carcinoma Treated With 90Y Transarterial Radioembolization.
Hwang SH; Hong HS; Kim D; Kim GM; Lee HW; Lee M; Kim DY; Park MA; Yun M
Clin Nucl Med; 2022 Jun; 47(6):e437-e443. PubMed ID: 35384891
[TBL] [Abstract][Full Text] [Related]
12. FDG PET/CT metabolic tumor volume and total lesion glycolysis predict prognosis in patients with advanced lung adenocarcinoma.
Chung HW; Lee KY; Kim HJ; Kim WS; So Y
J Cancer Res Clin Oncol; 2014 Jan; 140(1):89-98. PubMed ID: 24194352
[TBL] [Abstract][Full Text] [Related]
13. Metabolic tumour burden assessed by ¹⁸F-FDG PET/CT associated with serum CA19-9 predicts pancreatic cancer outcome after resection.
Xu HX; Chen T; Wang WQ; Wu CT; Liu C; Long J; Xu J; Zhang YJ; Chen RH; Liu L; Yu XJ
Eur J Nucl Med Mol Imaging; 2014 Jun; 41(6):1093-102. PubMed ID: 24522797
[TBL] [Abstract][Full Text] [Related]
14. The correlation of
Qu YH; Long N; Ran C; Sun J
Clin Transl Oncol; 2021 Mar; 23(3):620-627. PubMed ID: 32683540
[TBL] [Abstract][Full Text] [Related]
15. Alternative volumetric PET pjmirometers for evaluation of breast cancer cases with 18F-FDG PET/CT imaging: Metabolic tumour volume and total lesion glycolysis.
Arslan E; Can Trabulus D; Mermut Ö; Şavlı TC; Çermik TF
J Med Imaging Radiat Oncol; 2021 Feb; 65(1):38-45. PubMed ID: 33084216
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis measured by 18F-FDG PET/CT in salivary gland carcinomas.
Ryu IS; Kim JS; Roh JL; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
J Nucl Med; 2013 Jul; 54(7):1032-8. PubMed ID: 23670902
[TBL] [Abstract][Full Text] [Related]
17. Prognostic role of metabolic 18F-FDG PET/CT parameters and hematological prognostic indicators in patients with colorectal cancer.
Cengiz A; Yersal Ö; Ömürlü İK; Yürekli Y
Indian J Cancer; 2023; 60(2):224-229. PubMed ID: 37530245
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of 18F-FDG-PET/CT parameters in patients with pancreatic carcinoma: A systematic review and meta-analysis.
Zhu D; Wang L; Zhang H; Chen J; Wang Y; Byanju S; Liao M
Medicine (Baltimore); 2017 Aug; 96(33):e7813. PubMed ID: 28816978
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis on Preoperative 18F-FDG PET/CT in Patients With Very Early and Early Hepatocellular Carcinoma.
Hwang SH; Lee JW; Cho HJ; Kim KS; Choi GH; Yun M
Clin Nucl Med; 2017 Jan; 42(1):34-39. PubMed ID: 27775949
[TBL] [Abstract][Full Text] [Related]
20. Role of Various Metabolic Parameters Derived From Baseline 18F-FDG PET/CT as Prognostic Markers in Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy.
Sharma A; Mohan A; Bhalla AS; Sharma MC; Vishnubhatla S; Das CJ; Pandey AK; Sekhar Bal C; Patel CD; Sharma P; Agarwal KK; Kumar R
Clin Nucl Med; 2018 Jan; 43(1):e8-e17. PubMed ID: 29112011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
